The integration of these two areas aims to enable the development of predictive and prognostic biomarkers in patients with Ovarian cancer.
Patients with findings suspicious for ovarian cancer or with a definite diagnosis of the disease usually undergo computed tomography (CT) scans as their standard-of-care imaging to assess the extent of the disease. We are collaborating with molecular oncology and computational groups to extract quantitative data from these images (radiomics) and combine them with ctDNA isolated from blood samples of these patients to develop tools that predict response to chemotherapy as well as survival in these patients. These studies also help us understand which features of ovarian cancer affect the extent of ctDNA shedding into circulation and how molecular features of ovarian cancer affect tumour appearance on imaging.
Further information on the Integration of Radiomics and Circulating Tumour DNA (ctDNA) project.
The Mark Foundation Institute for Integrated Cancer Medicine (MFICM) at the University of Cambridge aims to revolutionise cancer care by affecting patients along their treatment pathway.